Physician profile
Benjamin M Teller
NPI 1447282702
$3,851.59
in general payments reported to CMS, 2019-2025
21 companies · $681 in 2025
The $681 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $240 · 2021: $425 · 2022: $415 · 2023: $925 · 2024: $954 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400 · Entertainment: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.54 |
| Entertainment | $160.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $631.83 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $550.69 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Bausch & Lomb Americas INC. | $527.91 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $319.66 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $265.72 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $260.99 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $226.70 | 2019-2021 | |
| Optos, INC. | $160.48 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $149.51 | 2019-2024 | Myday Contact Lens |
| Dompe US, INC. | $132.59 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $126.52 | 2021-2023 | Cequa |
| Allergan, INC. | $124.85 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $117.62 | 2021-2024 | Spectacle Lenses, Contact Lens |
| Kala Pharmaceuticals, INC. | $67.16 | 2021 | |
| Harrow Eye, LLC | $46.21 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $38.78 | 2022 | |
| Abbvie INC. | $26.72 | 2023 | Vuity, Lumigan, Alphagan P |
| Thea Pharma INC. | $24.04 | 2023 | |
| Biotissue Holdings INC. | $23.09 | 2024 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Teller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.